Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer

Schmid, Peter, Adams, Sylvia, Rugo, Hope S., Schneeweiss, Andreas, Barrios, Carlos H., Iwata, Hiroji, Diéras, Véronique, Hegg, Roberto +10 more·2018·New England Journal of Medicine

DOI 10.1056/nejmoa1809615

Cited by (1,010)

Items 201–300 of 1,010

Neurologic complications of immune checkpoint inhibitors
Alexandra M. Haugh, John C. Probasco, Douglas Buckner Johnson · 2020 · Expert Opinion on Drug Safety
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016
Élise Deluche, Alison Antoine, Thomas Bachelot, Audrey Lardy-Cléaud, Veronique C Dieras, Etienne G.C. Brain, Marc Debled, William Jacot, Marie‐Ange Mouret‐Reynier, Anthony Gonçalvès et al. · 2020 · European Journal of Cancer
FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer
Yun Huang, Hailiang Zhang, Zhi‐Ling Li, Tian Du, Yuhong Chen, Yan Wang, Huan-he Ni, Kaiming Zhang, Jia Mai, Bingxin Hu et al. · 2021 · Nature Communications
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Nicola Gaynor, John Paul Crown, Denis Martin Collins · 2020 · Seminars in Cancer Biology
The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer
Stephanie L. Goff, David N. Danforth · 2020 · Clinical Breast Cancer
Intratumoral Immunotherapy for Early-stage Solid Tumors
Wan Xing Hong, Sarah Haebe, Andrew Stephen Lee, Christoph Benedikt Westphalen, Jeffrey Allen Norton, Wen Jiang, Ronald Levy · 2020 · Clinical Cancer Research
Current issues and perspectives in PD-1 blockade cancer immunotherapy
Kenji Chamoto, Ryusuke Hatae, Tasuku Honjo · 2020 · International Journal of Clinical Oncology
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Romualdo Barroso‐Sousa, Tanya Elizabeth Keenan, Sònia Pernas, Pedro Exman, Esha Jain, Ana Christina Garrido-Castro, Melissa E. Hughes, Brittany Bychkovsky, Renato Umeton, Janet L. Files et al. · 2020 · Clinical Cancer Research
Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis
Nandini Verma, Yaron Vinik, Ashish Saroha, Nishanth Ulhas Nair, Eytan Ruppin, Gordon Brent Mills, Thomas Karn, Vinay Dubey, Lohit Khera, Harsha Raj et al. · 2020 · Science Advances
The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation
Man Shang, Huijie Yang, Ran Yang, Tao Chen, Yuan Fu, Yeyi Li, Xian-Long Fang, Kangjian Zhang, Zhang Jianju, Hui Li et al. · 2021 · Nature Communications
Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer
Maria Florencia Mercogliano, Sofía Bruni, Patricia V. Elizalde, Roxana Schillaci · 2020 · Frontiers in Oncology
Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer
Qianhui Xu, Shaohuai Chen, Yuanbo Hu, Wen Huang · 2021 · Frontiers in Immunology
Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment
Joshua Jing Xi Li, Julia Y. Tsang, Gary Man-Kit Tse · 2021 · Cancers
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
Manuela Terranova-Barberio, Nela Pawłowska, Mallika Dhawan, Mark M. Moasser, Amy Jo Chien, Michelle Melisko, Hope S. Rugo, Roshun Rahimi, Travis Ryan Deal, ADIL I. DAUD et al. · 2020 · Nature Communications
Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
Pascale Hubert, Patrick Roncarati, Stephanie Demoulin, Charlotte Pilard, Marie Ancion, Célia Reynders, Thomas Lerho, Diane Bruyère, Alizée Lebeau, Coraline Radermecker et al. · 2021 · Journal for ImmunoTherapy of Cancer
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Philippe Georges Aftimos, Mafalda Oliveira, Alexandre Irrthum, Debora Fumagalli, Christos P. Sotiriou, Einav Nili Gal‐Yam, Mark E. Robson, Justin Ndozeng, Angelo Di Leo, Eva Ciruelos et al. · 2021 · Cancer Discovery
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
Preeti Narayan, Sakar Wahby, Jennifer J. Gao, Laleh Amiri‐Kordestani, Amna Ibrahim, Erik W. Bloomquist, Shenghui W. Tang, Yuan Xu, Jiang Liu, Wentao Fu et al. · 2020 · Clinical Cancer Research
Chemo-Immunotherapy: A New Trend in Cancer Treatment
Christian Sordo‐Bahamonde, Seila Lorenzo‐Herrero, Ana Pilar González, Alejandra Martínez‐Pérez, Juan Pablo Rodrigo, Juana Maria Garcia-Pedrero, Segundo R. Gonzalez · 2023 · Cancers
Immunotherapy: A Challenge of Breast Cancer Treatment
Marilina García‐Aranda, Maximino Redondo · 2019 · Cancers
A review of prognostic and predictive biomarkers in breast cancer
Elaheh Tarighati, Hadi Keivan, Hojjat Mahani · 2022 · Clinical and Experimental Medicine
Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
Joe Mehanna, Fadi Haddad, Roland Eid, Matteo Lambertini, Hampig Raphaël Kourié · 2019 · International Journal of Women s Health
The Immunology of Hormone Receptor Positive Breast Cancer
Jonathan Goldberg, Ricardo Pastorello, Tuulia Vallius, Janae A. Davis, Yvonne Xiaoyong Cui, Judith Agudo, Adrienne Gropper Waks, Tanya Elizabeth Keenan, Sandra S. McAllister, Sara M. Tolaney et al. · 2021 · Frontiers in Immunology
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
Jii Bum Lee, Hye Ryun Kim, Sang‐Jun Ha · 2022 · Immune Network
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study
Geoerger, Birgit, Zwaan, C Michel, Marshall, Lynley V, Michon, Jean, Bourdeaut, Franck, Casanova, Michela, Corradini, Nadège, Rossato, Gianluca, Farid-Kapadia, Mufiza, Shemesh, Colby S et al. · 2020 · The Lancet Oncology
Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy
Sheera R. Rosenbaum, Nicole A. Wilski, Andrew E. Aplin · 2021 · Cancer Discovery
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Merry Jennifer Markham, KERRI WACHTER, Neeraj Agarwal, Monica M. Bertagnolli, Susan Marina Chang, William Dale, Catherine Diefenbach, Carlos Rodriguez Galindo, Daniel J. George, Timothy D. Gilligan et al. · 2020 · Journal of Clinical Oncology
Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically
Shawn C. Chafe, Paul C. McDonald, Saeed Saberi, Oksana Nemirovsky, Geetha Venkateswaran, Samantha Burugu, Dongxia Gao, Alberto Delaidelli, Alastair Hugh Kyle, Jennifer H.E. Baker et al. · 2019 · Cancer Immunology Research
HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
Jian Wang, hao-Ting sun, Q. Zeng, Xue-Jun Guo, Hui Wang, Huan Liu, Zhong-Yi Dong · 2019 · Scientific Reports
Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
Sima Lev · 2020 · Biochemical Society Transactions
Single-cell RNA sequencing reveals cell heterogeneity and transcriptome profile of breast cancer lymph node metastasis
Kun Xu, Runtian Wang, Hui Xie, Longfei Hu, Cong Wang, Jiali Xu, Chengjun Zhu, Yiqiu Liu, Fangyan Gao, Xintong Li et al. · 2021 · Oncogenesis
Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation
Zhi‐Ling Li, Hai‐Liang Zhang, Yun Huang, Jun-Hao Huang, Peng Sun, Ningning Zhou, Yuhong Chen, Jia Mai, Yan Wang, Yan Yu et al. · 2020 · Nature Communications
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Thomas Bachelot, Thomas Filleron, Ivan Bièche, Mónica Arnedos, Mario Campone, Florence Dalenc, Florence Coussy, Marie‐Paule Sablin, Marc Debled, Claudia Lefeuvre‐Plesse et al. · 2021 · Nature Medicine
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
Veronica Mollica, Alessandro Rizzo, Andrea Marchetti, Valentina Tateo, Elisa Tassinari, Matteo Rosellini, Raffaella Massafra, Matteo Santoni, Francesco Massari · 2023 · Clinical and Experimental Medicine
Immunotherapy in Breast Cancer
Kathrin Dvir, Sara Barnato Giordano, José Pablo Leone · 2024 · International Journal of Molecular Sciences
Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer
Sceneay, Jaclyn, Goreczny, Gregory J., Wilson, Kristin, Morrow, Sara, DeCristo, Molly J., Ubellacker, Jessalyn M., Qin, Yuanbo, Laszewski, Tyler, Stover, Daniel G., Barrera, Victor et al. · 2019 · Cancer Discovery
Recent treatment progress of triple negative breast cancer
Changqing Yang, Jie Liu, Shi‐Qi Zhao, Zhu Kun, Gong Zi-Qian, Ran Xu, Hui‐Meng Lu, Ren‐Bin Zhou, Gang Zhao, Da‐Chuan Yin et al. · 2019 · Progress in Biophysics and Molecular Biology
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond
Ricardo Lima Barros Costa, Brian J. Czerniecki · 2020 · npj Breast Cancer
Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape
Salvadori, Giulia, Zanardi, Federica, Iannelli, Fabio, Lobefaro, Riccardo, Vernieri, Claudio, Longo, Valter D. · 2021 · Cell Metabolism
The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
Linda Quatrini, Francesca Romana Mariotti, Enrico Munari, Nicola Tumino, Paola Vacca, Lorenzo Moretta · 2020 · Cancers
Oleandrin, a cardiac glycoside, induces immunogenic cell death via the PERK/elF2α/ATF4/CHOP pathway in breast cancer
Xiaoxi Li, Jian Zheng, Shi Chen, Fandong Meng, Jing Ning, Shulan Sun · 2021 · Cell Death and Disease
CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers
Tim Kong, Ryuhjin Ahn, Kangning Yang, Xianbing Zhu, Zheng Fu, Geneviève Morin, Rachel Bramley, Nikki C. Cliffe, Yibo Xue, Hellen Kuasne et al. · 2019 · Cancer Research
Open-label, Phase I Study of Nivolumab Combined with nab -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Zev A. Wainberg, Howard S. Höchster, Edward Jae-Hoon Kim, Ben George, Aparna Kaylan, Elena Gabriela Chiorean, David Michael Waterhouse, Martin Guiterrez, Aparna R. Parikh, Rishi Jain et al. · 2020 · Clinical Cancer Research
Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance
Raschi, Emanuel, Gatti, Milo, Gelsomino, Francesco, Ardizzoni, Andrea, Poluzzi, Elisabetta, De Ponti, Fabrizio · 2020 · Targeted Oncology
The role of RNA methylation in tumor immunity and its potential in immunotherapy
Yan Li, Haoer Jin, Qingling Li, Liangrong Shi, Yitao Mao, Luqing Zhao · 2024 · Molecular Cancer
Emerging therapies for non-small cell lung cancer
Chao Zhang, Natasha B. Leighl, Yi-Long Lung Cancer Wu, Wen‐Zhao Zhong · 2019 · Journal of Hematology & Oncology
PD-L1 status in breast cancer: Current view and perspectives
Semir Vranić, Farhan Sachal Cyprian, Zoran Gatalica, Juan Palazzo · 2019 · Seminars in Cancer Biology
Nanomedicine and macroscale materials in immuno-oncology
Qingxue Sun, Matthias Barz, Bruno G. De Geest, Mustafa Diken, Wim E. Hennink, Fabian M. Kiessling, Twan Lammers, Yang Shi · 2018 · Chemical Society Reviews
Molecular stratification within triple-negative breast cancer subtypes
Dong‐Yu Wang, Zhe Jiang, Yaacov Ben‐David, James Robert Woodgett, Eldad Zacksenhaus · 2019 · Scientific Reports
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Sara M. Tolaney, Romualdo Barroso‐Sousa, Tanya Elizabeth Keenan, Tianyu Li, Lorenzo Trippa, Inês Vaz-Luís, Gerburg M. Wulf, Laura M. Spring, Natalie Faye Sinclair, Chelsea Andrews et al. · 2020 · JAMA Oncology
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer
Sakar Wahby, Lola A. Fashoyin‐Aje, Christy L. Osgood, Joyce Cheng, Mallorie H. Fiero, Lijun Zhang, Shenghui W. Tang, Salaheldin S. Hamed, Pengfei Song, Rosane Charlab et al. · 2020 · Clinical Cancer Research
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
James W. Opzoomer, Dominika Sosnowska, Joanne E. Anstee, James F. Spicer, James N. Arnold · 2019 · Frontiers in Immunology
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
Jin Sun Lee, Susan Elaine Yost, Yuan Yuan · 2020 · Cancers
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Aleix Prat, Anwesha Chaudhury, Nadia Solovieff, Laia Paré, Débora Martinez, Núria Chic, Olga Martínez‐Sáez, Fara Brasó‐Maristany, Agnes Lteif, Tetiana Taran et al. · 2021 · Journal of Clinical Oncology
Mast Cells: A New Frontier for Cancer Immunotherapy
Jake N. Lichterman, Sangeetha Meda Reddy · 2021 · Cells
The potential of activator protein 1 (AP-1) in cancer targeted therapy
Dandan Song, Yan Lian, Lin Zhang · 2023 · Frontiers in Immunology
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla Kaliopi Brastianos, Eudocia Q. Lee, Justine Vanessa Cohen, Sara M. Tolaney, NU Lin, Nancy Wang, Ugonma Nnenna Chukwueke, Michael D. White, Naema Nayyar, Albert Eusik Kim et al. · 2020 · Nature Medicine
Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future
Mariko Asaoka, Shipra Gandhi, Takashi Ishikawa, Kazuaki Takabe · 2020 · Breast Cancer Basic and Clinical Research
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update
Norah Lynn Henry, Mark R. Somerfield, Zoneddy Ruiz Dayao, ANTHONY D. ELIAS, Kevin M. Kalinsky, Lisa M. McShane, Beverly Moy, Ben Ho Park, Kelly M. Shanahan, Priyanka Sharma et al. · 2022 · Journal of Clinical Oncology
Targeted therapy for breast cancer: An overview of drug classes and outcomes
Aaron T. Jacobs, Diana Martinez Castaneda-Cruz, Mark M. Rose, Linda Connelly · 2022 · Biochemical Pharmacology
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
Matteo Santoni, Alessandro Rizzo, Jakub Kucharz, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Elisa Tassinari, Fernando Sabino Marques Monteiro, Andrey Soares, Javier Molina‐Cerrillo et al. · 2023 · Cancer Immunology Immunotherapy
Cancer-Associated Fibroblasts: Understanding Their Heterogeneity
Kévin Louault, Rongrong Li, Yves Albert DeClerck · 2020 · Cancers
Immunotherapy for early triple negative breast cancer: research agenda for the next decade
Paolo Tarantino, Chiara Corti, Peter Schmid, Javier Cortés, Elizabeth Ann Mittendorf, Hope S. Rugo, Sara M. Tolaney, Giampaolo Bianchini, Fabrice André, Giuseppe Curigliano · 2022 · npj Breast Cancer
Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
Sara Verdura, Elisabet Cuyàs, Èric Cortada, Joan Brunet, Eugeni López‐Bonet, Begoña Martı́n-Castillo, Joaquim Bosch‐Barrera, José Antonio Encinar, Javier Abel Menéndez · 2020 · Aging
Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review
Claire H. Li, Vassiliki Karantza, Gursel Aktan, Mallika Lala · 2019 · Breast Cancer Research
Evolving cancer–niche interactions and therapeutic targets during bone metastasis
Robert L. Satcher, Xiang H.-F. Zhang · 2021 · Nature reviews. Cancer
The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies
Constantin N. Baxevanis, Sotirios P. Fortis, Sonia A. Perez · 2019 · Seminars in Cancer Biology
Radiogenomic-Based Survival Risk Stratification of Tumor Habitat on Gd-T1w MRI Is Associated with Biological Processes in Glioblastoma
Niha G. Beig, Kaustav Bera, Prateek Prasanna, Jacob T. Antunes, Ramón Correa, Salendra Singh, Anas Saeed Bamashmos, Marwa Ismail, Nathaniel M. Braman, Ruchika Verma et al. · 2020 · Clinical Cancer Research
Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer
Tanja Nadine Stüber, Razieh Monjezi, Lars Wallstabe, Johanna Kühnemundt, Sarah Nietzer, Gudrun Dandekar, Achim Wöckel, Hermann Einsele, Jörg Wischhusen, Michael Hudecek · 2020 · Journal for ImmunoTherapy of Cancer
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab -Paclitaxel–Treated Advanced Triple-Negative Breast Cancer
Hope S. Rugo, Sherene Loi, Sylvia Adams, Peter Schmid, Andreas Schneeweiß, Carlos H. Barrios, Hiroji Iwata, Veronique C Dieras, Eric P. Winer, Mark M. Kockx et al. · 2021 · JNCI Journal of the National Cancer Institute
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
Chenyi Luo, Peipei Wang, Siqi He, Jingjing Zhu, Yuanyuan Shi, Jianxun Wang · 2022 · Frontiers in Oncology
Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies
Maria Eduarda Salgado Carvalho, Şule Canberk, Fernando Carlos Schmitt, Nuno Vale · 2025 · Cancers
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Ana Christina Garrido-Castro, Cristina Saura, Romualdo Barroso‐Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquín Gavilá, Violeta Serra, Aleix Prat, Laia Paré et al. · 2020 · Breast Cancer Research
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
Aena Patel, Nisha G Unni, Yan Shen Peng · 2020 · Cancers
Novel antibody–drug conjugates for triple negative breast cancer
Aiko Nagayama, Neelima Vidula, Leif William Ellisen, Aditya Bardia · 2020 · Therapeutic Advances in Medical Oncology
Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
Junyan Li, Yu‐Pei Chen, Ying‐Qin Li, Na Liu, Jun Ma · 2021 · Molecular Cancer
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
Nicoletta Colombo, Elena Cosenza Biagioli, Kenichi Harano, Francesca Galli, Emma R. Hudson, Yoland Catherine Antill, Chel Hun Choi, Manuela Rabaglio, Frederic Marmé, Christian Marth et al. · 2024 · The Lancet Oncology
Fucoidan-based, tumor-activated nanoplatform for overcoming hypoxia and enhancing photodynamic therapy and antitumor immunity
Chu‐Hung Chung, Kun-Ying Lu, Wei-Cheng Lee, Wen‐Jing Hsu, Wen-Fu Lee, Jia-Zih Dai, Pei‐Wei Shueng, Cheng‐Wei Lin, Fwu‐Long Mi · 2020 · Biomaterials
Immunotherapies and Combination Strategies for Immuno-Oncology
Cody Barbari, Tyler Fontaine, Priyanka Parajuli, Narottam Lamichhane, Silvia Jakubski, Purushottam Lamichhane, Rahul R. Deshmukh · 2020 · International Journal of Molecular Sciences
Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance
Taniya Saha, Kiven Erique Lukong · 2022 · Frontiers in Oncology
Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies
Oliver Kepp, Aurélien Marabelle, Laurence Zitvogel, Guido Kroemer · 2019 · Nature Reviews Clinical Oncology
Dissecting the biological heterogeneity of HER2-positive breast cancer
Francesco Schettini, Aleix Prat · 2021 · The Breast
Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer
Yuanyuan Zhang, Hongyan Chen, Hongnan Mo, Ning Zhao, Xiaoying Sun, Baolin Liu, Ranran Gao, Binghe Xu, Zemin Zhang, Zhihua Liu et al. · 2025 · Cancer Cell
Advances and prospects of biomarkers for immune checkpoint inhibitors
Hirohito Yamaguchi, Jung-Mao Hsu, Linlin Sun, Shao‐Chun Wang, Mien‐Chie Hung · 2024 · Cell Reports Medicine
Intratumoral Immunotherapy: From Trial Design to Clinical Practice
Stéphane Champiat, Lambros Tselikas, Siham Farhane, Thibault Raoult, Matthieu Texier, Émilie Lanoy, Christophe Massard, Caroline Robert, Samy Ammari, Thierry de Baère et al. · 2020 · Clinical Cancer Research
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
Alessandro Rizzo, Veronica Mollica, Valentina Tateo, Elisa Tassinari, Andrea Marchetti, Matteo Rosellini, Raffaele De Luca, Matteo Santoni, Francesco Massari · 2023 · Cancer Immunology Immunotherapy
Dendritic Cells in Cancer Immunology and Immunotherapy
Laura Hato, Ángel Vizcay Atienza, Iñaki Eguren‐Santamaría, José Luis Perez‐Gracia, Javier Rodríguez, Jaime Gállego Pérez‐Larraya, Pablo Sarobe, Susana Inogés, Ascensión López Dı́az de Cerio, Marta Santisteban · 2024 · Cancers
The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer?
Priyanka Bhateja, Mathew Amprayil Cherian, Sarmila Majumder, Bhuvaneswari Ramaswamy · 2019 · Cancers
Overview of recent advances in metastatic triple negative breast cancer
David O'Reilly, Maha AlSendi, Catherine Margaret Kelly · 2021 · World Journal of Clinical Oncology
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi K Chugh, Scott M. Schuetze, Mary Dickinson Chamberlin, Barbara J. Haley, Anna Maria Storniolo, Mridula P. Reddy et al. · 2021 · Clinical Cancer Research
Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
Jieun Lee · 2023 · Journal of Clinical Medicine
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Haibo Wang, Yongmei Yin, Xiaojia Wang, Xin Min ZHOU et al. · 2024 · Nature Medicine
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance
Jing Wang, Baizhou Li, Meng Luo, Jia Huang, Kun Zhang, Shu Zheng, Suzhan Zhang, Jiaojiao Zhou · 2024 · Signal Transduction and Targeted Therapy
The NF-KB pathway and endocrine therapy resistance in breast cancer
Phungern Khongthong, Antonia Kathryn Roseweir, Joanne Edwards · 2019 · Endocrine Related Cancer
Molecular subtypes and precision treatment of triple-negative breast cancer
Shen Zhao, Wen‐Jia Zuo, Zhi‐Ming Shao, Yizhou Jiang · 2020 · Annals of Translational Medicine
Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice
Yudong Song, Luke F. Bugada, Ruiting Li, Hongxiang Hu, Luchen Zhang, Chengyi Li, Hebao Yuan, Krishani Kumari Rajanayake, Nathan A. Truchan, Fei Wen et al. · 2022 · Science Translational Medicine
Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
Emily Reisenbichler, Gang Han, Andrew M. Bellizzi, Veerle Bossuyt, Jane E. Brock, Kimberly S. Cole, Oluwole Fadare, Omar Hameed, Krisztina Z. Hanley, Beth T. Harrison et al. · 2020 · Modern Pathology
The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer
Masanori Oshi, Hideo Takahashi, Yoshihisa Tokumaru, Li Yan, Omar Maen Rashid, Masayuki Nagahashi, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe · 2020 · Cells
Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
Jens Huober, Carlos H. Barrios, Naoki Niikura, Michał Jarząb, Yuan‐Ching Chang, Shannon Leigh Huggins-Puhalla, José Luiz Pedrini, Lyudmila Zhukova, Vilma Graupner, Daniel Eiger et al. · 2022 · Journal of Clinical Oncology
Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
Sunny Kumar, Mouli Chatterjee, Pratyasha Ghosh, Kirat Kumar Ganguly, Malini Basu, Mrinal K. Ghosh · 2022 · Genes & Diseases
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
Eriseld Krasniqi, Giacomo Barchiesi, Laura Pizzuti, Marco Mazzotta, Aldo Venuti, Marcello Maugeri‐Saccà, Giuseppe Sanguineti, Gioia Massimiani, Domenico Sergi, Silvia Carpano et al. · 2019 · Journal of Hematology & Oncology